Workshop Day

Tuesday, August 27

Workshop A

Overlap Between IPF & Other Fibrotic Diseases:
Pathophysiology & Target Identification in Fibrosis

9:00am – 12:00pm

With better screens and better tools giving better outcomes, critically assessing molecular prognostic biomarkers of fibrosis can inform an arsenal of non-invasive techniques and innovate drug development.

This workshop will explore:
• Overlap and relationships between organ-specific pathological fibrosis
• Common pathways to different organ-specific fibrosis; is there a central regulator of fibrosis across several organs that we can target?
• Combination therapy to treat fibrosis; specifically, bi-functional molecules regulating both inflammation and fibrosis

Workshop Leader

Sunhwa Kim

Sunhwa Kim
Principal Scientist
Merck

Workshop B

Adding Radiology to the Pulmonary Fibrosis Equation
12:30pm – 3:30pm

Advancements in the application of imaging techniques to inform and enrich clinical trial decisions goes hand-in-hand with the next generation of IPF drug development.

Following on from last IPF Summit’s workshop, continue the conversation on imaging’s capacity to:
• Advance biomarker identification
• Differentially diagnoses patients
• Improve clinical translation

Workshop Leader

Mary Salvatore

Mary Salvatore
Associate Professor – Thoracic Radiology
Mount Sinai Medical Center

Workshop C

Working Meeting of the Prognostic Lung Fibrosis Consortium (PROLIFIC)
4:00pm – 7:00pm

As clinical trial activity gears up, developing well-characterized assays to determine clinical utility and commercial potential of current predictive or prognostic biomarkers is becoming increasingly important.

This expert led meeting will cover:
• Evaluation of additional inflammation markers for the PROLIFIC list
• Update on Clinical Testing Laboratories selection and contracting process
• Execution of the collaboration agreement

Workshop Leader

Peter Schafer

Peter Schafer
Executive Director, Translational Development
Celgene